Treatment of Hereditary Angioedema with Danazol: Reversal of Clinical and Biochemical Abnormalities

New England Journal of Medicine

Volumn 295, Issue 26, 1976, Pages 1444-1448

  Gelfand, Jeffrey A ^a   Sherins, Richard J ^a   Alling, David W ^a   Frank, Michael M ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4; DANAZOL; ETHISTERONE; FLUOXYMESTERONE; OXYMETHOLONE; PLACEBO;

ADVERSE DRUG REACTION; ANGIONEUROTIC EDEMA; CLINICAL STUDY; DOUBLE BLIND PROCEDURE; DRUG THERAPY; FACE; LARYNX; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; THERAPY; UPPER RESPIRATORY TRACT OBSTRUCTION;

EID: 0017053432     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM197612232952602     Document Type: Article

References (27)

1. Presented at the national meeting of the American Society for Clinical Investigation, Atlantic City, NJ, May 2, 1976.
2. Osler W: Hereditary angio-neurotic oedema. Am J Med Sci 95: 362–367, 1888
3. Landerman NS: Hereditary angioneurotic edema. I. Case reports with a review of the literature. J Allergy 33: 316–329, 1962
4. Donaldson VH, Rosen FS: Hereditary angioneurotic edema: a clinical survey. Pediatrics 37: 1017–1027, 1966
5. Frank MM, Gelfand JA, Atkinson JP: Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 84: 580–593, 1976
6. Donaldson VH, Evans RR: A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of Cl-esterase. Am J Med 35: 37–44, 1963
7. Rosen FS, Charache P, Pensky J, et al: Hereditary angioneurotic edema: two genetic variants. Science 148: 957–958, 1965
8. Nilsson IM, Andersson L, Björkman SE: Epsilon-aminocaproic acid (E-ACA) as a therapeutic agent based on 5 years’ clinical experience. Acta Med Scand [Suppl] 448: 1–46, 1966
9. Frank MM, Sergent JS, Kane MA, et al: Epsilon aminocaproic acid therapy of hereditary angioneurotic edema: a double blind study. N Engl J Med 286: 808–812, 1972
10. Sheffer AL, Austen KF, Rosen FS: Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 287: 452–454, 1972
11. Blohmé G: Treatment of hereditary angioneurotic oedema with tranexemic acid: a random double-blind cross-over study. Acta Med Scand 192: 293–298, 1972
12. Spaulding WB: Methyltestosterone therapy for hereditary episodic edema (hereditary angioneurotic edema). Ann Intern Med 53: 739–745, 1960
13. Davis PJ, Davis FB, Charache P: Long-term therapy of hereditary angioedema (HAE): preventive management with fluoxymesterone and oxymetholone in severely affected males and females. Johns Hopkins Med J 135: 391–398, 1974
14. Boyer JL, Preisig R, Zbinden G, et al: Guidelines for assessment of potential hepatotoxic effects of synthetic androgens, anabolic agents and progestagens in their use in males as antifertility agents. Contraception 13: 461–468, 1976
15. Sherins RJ, Gandy HM, Thorslund TW, et al: Pituitary and testicular function studies. I. Experience with a new gonadal inhibitor, 17α-pregn-4-en-20-yno-(2,3-d) isoxazol-17-ol (Danazol). J Clin Endocrinol Metab 32: 522–531, 1971
16. Greenblatt RB, Dmowski WP, Mahesh VB, et al: Clinical studies with an antigonadotropin — Danazol. Fertil Steril 22: 102–112, 1971
17. Wood GP, Wu CH, Flickinger GL, et al: Hormonal changes associated with Danazol therapy. Obstet Gynecol 45: 302–304, 1975
18. Lee PA, Thompson RG, Migeon CJ, et al: The effect of Danazol in sexual precocity. Johns Hopkins Med J 137: 265–269, 1975
19. Andrews MC, Wentz achéal: The effects of Danazol on gonadotropins and steroid blood levels in normal and anovulatory women. Am J Obstet Gynecol 121: 817–828, 1975
20. Wentz achéal, Jones GS, Sapp KC: Investigation of Danazol as a contraceptive agent. Contraception 13: 619–621, 1976
21. Efron B: Forcing a sequential experiment to be balanced. Biometrika 58: 403–417, 1971
22. Gigli I, Ruddy S, Austen KF: The stoichiometric measurement of the serum inhibitor of the first component of complement by the inhibition of immune hemolysis. J Immunol 100: 1154–1164, 1968
23. Gaither TA, Alling DW, Frank MM: A new one-step method for the functional assay of the fourth component (C4) of human and guinea pig complement. J Immunol 113: 574–583, 1974
24. Laurell A-B, Martensson U: Cl inactivator protein complexed with albumin in plasma from a patient with angioneurotic edema. Eur J Immunol 1: 146–149, 1971
25. Rosse WF, Logue GL, Silberman HR: The effect of synthetic androgens on the clinical course and Cl esterase inhibitor (Cl INH) levels in hereditary angioneurotic edema (HANE). Clin Res 24: 482A, 1976
26. Rosse WF, Logue GL, Silberman HR, et al: The effect of synthetic androgens in hereditary angioneurotic edema: alteration of C1 inhibitor and C4 levels. Trans Assoc Am Physicians (in press)
27. Johnson AM, Alper CA, Rosen FS, et al: C1 inhibitor: evidence for decreased hepatic synthesis in hereditary angioneurotic edema. Science 173: 553–554, 1971